Here’s what you should know.
1. The study will assess the safety, efficacy and tolerability of the joint therapy approach for NASH.
2. NASH is the fastest growing cause of liver cancer and liver transplants in the United States.
3. Allergan did not disclose terms of the deal.
4. There are currently no treatments for NASH.
More articles on gastroenterology:
University of Arizona researchers making dual-view endoscope: 3 key notes
Payment Model Technical Advisory Committee approves Project Sonar as an alternative payment model
GI leader to know: Dr. Brent Gray of Central Texas Gastroenterology Consultants
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
